In addition to advocating TRPS1 as a new target for the development of chemosensitizers for BC, our data provide evidence for the beneficial effect of clinically approved PARP inhibitor drugs in the treatment of chemo-refractory BC with elevated TRPS1, thus providing a ready-to-use pharmacological approach to overcome chemo-failure in patients with BC. Here, TRPS1 is linked to breast cancer.